Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRITAX study of intratumoral pharmacokinetics of CriPec docetaxel versus Taxotere
NL-OMON47152Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of docetaxel in Non-hematologic malignancy (2 arms), sponsored by Erasmus MC. Primary endpoint: Intratumoral docetaxel concentration difference. Started Apr 2017; status: active, not recruiting.
02
Drugs
docetaxel
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on NL-OMON47152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47152.